202 related articles for article (PubMed ID: 37961552)
1. Colloidal aggregation confounds cell-based Covid-19 antiviral screens.
Glenn IS; Hall LN; Khalid MM; Ott M; Shoichet BK
bioRxiv; 2023 Oct; ():. PubMed ID: 37961552
[TBL] [Abstract][Full Text] [Related]
2. Colloidal Aggregation Confounds Cell-Based Covid-19 Antiviral Screens.
Glenn IS; Hall LN; Khalid MM; Ott M; Shoichet BK
J Med Chem; 2024 Jun; 67(12):10263-10274. PubMed ID: 38864383
[TBL] [Abstract][Full Text] [Related]
3. Colloidal aggregators in biochemical SARS-CoV-2 repurposing screens.
Oâ Donnell HR; Tummino TA; Bardine C; Craik CS; Shoichet BK
bioRxiv; 2021 Aug; ():. PubMed ID: 34494023
[TBL] [Abstract][Full Text] [Related]
4. Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
O'Donnell HR; Tummino TA; Bardine C; Craik CS; Shoichet BK
J Med Chem; 2021 Dec; 64(23):17530-17539. PubMed ID: 34812616
[TBL] [Abstract][Full Text] [Related]
5. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
[TBL] [Abstract][Full Text] [Related]
6. Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19.
Shrimp JH; Janiszewski J; Chen CZ; Xu M; Wilson KM; Kales SC; Sanderson PE; Shinn P; Schneider R; Itkin Z; Guo H; Shen M; Klumpp-Thomas C; Michael SG; Zheng W; Simeonov A; Hall MD
ACS Infect Dis; 2022 Jun; 8(6):1191-1203. PubMed ID: 35648838
[TBL] [Abstract][Full Text] [Related]
7. A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry.
Xu M; Pradhan M; Gorshkov K; Petersen JD; Shen M; Guo H; Zhu W; Klumpp-Thomas C; Michael S; Itkin M; Itkin Z; Straus MR; Zimmerberg J; Zheng W; Whittaker GR; Chen CZ
SLAS Discov; 2022 Mar; 27(2):86-94. PubMed ID: 35086793
[TBL] [Abstract][Full Text] [Related]
8. Identification of oral therapeutics using an AI platform against the virus responsible for COVID-19, SARS-CoV-2.
Bess A; Berglind F; Mukhopadhyay S; Brylinski M; Alvin C; Fattah F; Wasan KM
Front Pharmacol; 2023; 14():1297924. PubMed ID: 38186640
[No Abstract] [Full Text] [Related]
9. Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy.
Boytz R; Słabicki M; Ramaswamy S; Patten JJ; Zou C; Meng C; Hurst BL; Wang J; Nowak RP; Yang PL; Sattler M; Stone RM; Griffin JD; Gray NS; Gummuluru S; Davey RA; Weisberg E
J Med Virol; 2023 Jan; 95(1):e28157. PubMed ID: 36117402
[TBL] [Abstract][Full Text] [Related]
10. Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS-S and MERS-S pseudotyped particles.
Chen CZ; Xu M; Pradhan M; Gorshkov K; Petersen J; Straus MR; Zhu W; Shinn P; Guo H; Shen M; Klumpp-Thomas C; Michael SG; Zimmerberg J; Zheng W; Whittaker GR
bioRxiv; 2020 Aug; ():. PubMed ID: 32839777
[TBL] [Abstract][Full Text] [Related]
11. An Aggregation Advisor for Ligand Discovery.
Irwin JJ; Duan D; Torosyan H; Doak AK; Ziebart KT; Sterling T; Tumanian G; Shoichet BK
J Med Chem; 2015 Sep; 58(17):7076-87. PubMed ID: 26295373
[TBL] [Abstract][Full Text] [Related]
12. Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles.
Chen CZ; Xu M; Pradhan M; Gorshkov K; Petersen JD; Straus MR; Zhu W; Shinn P; Guo H; Shen M; Klumpp-Thomas C; Michael SG; Zimmerberg J; Zheng W; Whittaker GR
ACS Pharmacol Transl Sci; 2020 Dec; 3(6):1165-1175. PubMed ID: 33330839
[TBL] [Abstract][Full Text] [Related]
13. A Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19.
Shrimp JH; Janiszewski J; Chen CZ; Xu M; Wilson KM; Kales SC; Sanderson PE; Shinn P; Itkin Z; Guo H; Shen M; Klumpp-Thomas C; Michael SG; Zheng W; Simeonov A; Hall MD
bioRxiv; 2022 Feb; ():. PubMed ID: 35169799
[TBL] [Abstract][Full Text] [Related]
14. Colloidal aggregation: from screening nuisance to formulation nuance.
Ganesh AN; Donders EN; Shoichet BK; Shoichet MS
Nano Today; 2018 Apr; 19():188-200. PubMed ID: 30250495
[TBL] [Abstract][Full Text] [Related]
15. Colloidal aggregation causes inhibition of G protein-coupled receptors.
Sassano MF; Doak AK; Roth BL; Shoichet BK
J Med Chem; 2013 Mar; 56(6):2406-14. PubMed ID: 23437772
[TBL] [Abstract][Full Text] [Related]
16. Colloidal aggregation and the in vitro activity of traditional Chinese medicines.
Duan D; Doak AK; Nedyalkova L; Shoichet BK
ACS Chem Biol; 2015 Apr; 10(4):978-88. PubMed ID: 25606714
[TBL] [Abstract][Full Text] [Related]
17. Potential natural products that target the SARS-CoV-2 spike protein identified by structure-based virtual screening, isothermal titration calorimetry and lentivirus particles pseudotyped (Vpp) infection assay.
Chen GY; Pan YC; Wu TY; Yao TY; Wang WJ; Shen WJ; Ahmed A; Chan ST; Tang CH; Huang WC; Hung MC; Yang JC; Wu YC
J Tradit Complement Med; 2022 Jan; 12(1):73-89. PubMed ID: 34549024
[TBL] [Abstract][Full Text] [Related]
18. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
[TBL] [Abstract][Full Text] [Related]
19. The use of Pseudotyped Coronaviruses for the Screening of Entry Inhibitors: Green Tea Extract Inhibits the Entry of SARS-CoV-1, MERSCoV, and SARS-CoV-2 by Blocking Receptor-spike Interaction.
Joseph J; Karthika T; Das VRA; Raj VS
Curr Pharm Biotechnol; 2022; 23(8):1118-1129. PubMed ID: 34375189
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
